Gilteritinib leads to proteasomal degradation of MCL-1 and increased venetoclax sensitivity, and thus, the combination of venetoclax and gilteritinib may have a possible clinical role even in non-FLT3-mutated AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.